Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
LRMR
Strong SellLarimar Therapeutics, Inc. · Healthcare · United States · $421M · Avg Vol: $5M/d
COMPANY DESCRIPTION
Larimar Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel treatments for rare and severe diseases, with its primary candidate targeting Friedreich's ataxia. The company possesses proprietary technology and intellectual property around its therapeutic candidates for specific orphan diseases, addressing unmet medical needs. Larimar is a development-stage biotech firm with significant R&D risk and potential for substantial upside if clinical trials succeed.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | — | — | — | 41.7M | — |
| EPS | -2.95 | -0.57 | -0.36 | -1.32 | -2.27 | — | -2.01 | -1.35 | -1.06 | — |
| Shares | 17.7M | 103.9M | 103.9M | 63.8M | 83.1M | +369.2% | 103.9M | — | — | — |
| Debt | 6.0M | 5.4M | 5.5M | 5.1M | 4.1M | -9.3% | 5.0M | — | — | — |
| Equity | 64.4M | 110.9M | 81.7M | 171.8M | 78.1M | 4.9% | — | — | — | — |
| Op CF | -42.1M | -27.6M | -33.5M | -70.8M | -113.2M | — | -155.9M | — | — | — |
| Inv CF | 24.2M | -91.0M | 33.4M | -85.4M | 100.3M | — | — | — | — | — |
| Fin CF | 19.9M | 75.3M | 30.0K | 161.9M | 65.1M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of LRMR are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| LRMR | Larimar Therapeutics, Inc.(you) | $421M | 18 | Strong Sell |
| ENTA | Enanta Pharmaceuticals, Inc. | $411M | 17 | Strong Sell |
| FHTX | Foghorn Therapeutics Inc. | $408M | 16 | Strong Sell |
| DMAC | DiaMedica Therapeutics Inc. | $352M | 17 | Strong Sell |
| OBIO | Orchestra BioMed Holdings, Inc. | $327M | 18 | Strong Sell |
| EDIT | Editas Medicine, Inc. | $461M | 22 | Sell |
| AVIR | Atea Pharmaceuticals, Inc. | $442M | 23 | Sell |
| RCKT | Rocket Pharmaceuticals, Inc. | $388M | 13 | Strong Sell |
| IPSC | Century Therapeutics, Inc. | $384M | 23 | Sell |
| GALT | Galectin Therapeutics Inc. | $391M | 13 | Strong Sell |
Peer medians: ROE -25.6% · P/E 29.5x · Gross margin 58.7%